Insider Buying: YD Bio (NASDAQ:YDES) CEO Purchases $12,183.00 in Stock

YD Bio Limited (NASDAQ:YDES) CEO Ethan Phd Shen purchased 3,100 shares of YD Bio stock in a transaction dated Wednesday, September 9th. The stock was bought at an average price of $3.93 per share, for a total transaction of $12,183.00. Following the completion of the transaction, the chief executive officer directly owned 11,245,631 shares in the company, valued at $44,195,329.83. The trade was a 0.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

YD Bio Trading Down 0.5%

NASDAQ YDES traded down $0.02 on Thursday, reaching $3.90. The company had a trading volume of 633,162 shares, compared to its average volume of 95,569. YD Bio Limited has a 52 week low of $1.70 and a 52 week high of $25.00. The stock’s 50 day moving average is $2.94 and its 200-day moving average is $4.55.

YD Bio (NASDAQ:YDES) last issued its earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $0.42 million for the quarter.

Institutional Investors Weigh In On YD Bio

An institutional investor recently raised its stake in YD Bio stock. Cypress Capital Management LLC WY raised its position in YD Bio Limited (NASDAQ:YDES) by 9.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,690 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent filing with the SEC.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.